- $11.84m
- $33.91m
- $9.64m
- 28
- 51
- 72
- 48
2019 March 31st | R2020 March 31st | C2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.398 | 1.42 | 3.38 | 7.65 | 9.64 |
Cost of Revenue | |||||
Gross Profit | 0.15 | 0.486 | 1.27 | 4.57 | 5.44 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.99 | 12.3 | 16.8 | 26.8 | 25.1 |
Operating Profit | -8.59 | -10.9 | -13.5 | -19.2 | -15.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.59 | -11.1 | -15.5 | -29.1 | -18.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.59 | -11.1 | -15.5 | -29.1 | -18.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.59 | -11.1 | -15.5 | -29.1 | -18.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.59 | -11.3 | -16.5 | -30.2 | -19.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.54 | -1.89 | -2.61 | -3.84 | -2.25 |